Do We Still Need Patients In Tomorrow's Trials? Modeling Placebo Effect And Beyond

In a recent LinkedIn Live session, Derk Arts, CEO of Castor, joined forces with MaryAnne Rizk, CEO of Rizk Management Advisors, to explore the transformative impact of AI on clinical trials. The discussion provided an in-depth analysis of how advanced technologies are reshaping drug development and patient care, emphasizing the crucial balance between innovation and ethical responsibility to achieve better trial outcomes.

From the outset, both leaders concurred that AI is not merely an enhancement but a fundamental change in the way clinical trials are conceptualized and conducted. They then delved into several key areas, highlighting the potential benefits and challenges of integrating AI into the clinical research process. The conversation touched on the ways AI can streamline trial design, improve patient recruitment, and enhance data analysis while also addressing the ethical considerations necessary to ensure patient safety and integrity throughout the trial process.